<DOC>
	<DOCNO>NCT02291367</DOCNO>
	<brief_summary>This study compare relative bioavailability Duloxetine HCl delay release capsule 60 mg 'CYMBALTAÂ® ' delayed release capsule 60 mg ( Duloxetine HCl delay release capsule 60 mg ) healthy , adult , human subject fast condition monitor safety subject</brief_summary>
	<brief_title>Bioavailability Study Duloxetine Delayed-Release Capsules 60 mg Under Fasting Condition</brief_title>
	<detailed_description>Open label , randomize , two period , two treatment , two sequence , crossover , balance , single dose comparative oral bioavailability study healthy , adult , human subject fast condition</detailed_description>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>1 . Be healthy human 18 45 year 2 . Screened within 21 day prior administration first dose study drug 3 . Having BMI 18.5 24.9 weight kg/ height2 meter 4 . Be able communicate effectively study personnel 5 . Be able give Written inform consent participate study If subject female volunteer 6. child bear potential practicing acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine device ( IUD ) , abstinence . 7. postmenopausal least 1 year . 8. surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy perform subject ) . 1 . History allergic response Duloxetine relate drug . 2 . Have significant disease clinically significant abnormal finding screen , medical history , physical examination , laboratory evaluation , ECG &amp; Xray recording . 3 . Any disease condition might compromise haemopoeitic , gastrointestinal , renal , hepatic , cardiovascular , respiratory , central nervous system , diabetes , psychosis body system . 4 . History presence bronchial asthma . 5 . Use enzymemodifying drug within 30 day prior receive first dose study medication . 6 . History drug dependence , recent history alcoholism moderate alcohol use . 7 . Smokers , smoke equal 10 cigarette per day equal 20 biddy per day refrain smoke study period . 8 . History difficulty donate blood difficulty accessibility vein . Donation blood ( I unit : 350 mL/450 mL ) within 90 day prior receive first dose study medication . 9 . A positive hepatitis screen ( include subtypes A , B , C &amp; E ) 10 . A positive test result HIV antibody and/or syphilis ( RPR/VDRL ) . 11 . The receipt investigational product , participation drug research study within period 90 day prior frst dose study medication administration . 12 . Female volunteer demonstrate positive pregnancy screen 13 . Female volunteer currently breastfeed 14 . Female volunteer willing use contraception study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>